China Pharmaceutical Holdings has signed a strategic cooperation agreement with Gilead Sciences

September 8, China Pharmaceutical Holdings Co., Ltd. ("China Pharmaceutical Holdings") and Gilead Sciences Co., Ltd. ("Gilead Sciences") signed a strategic cooperation agreement in Shanghai. The two sides will make full use of their respective advantages in pharmaceutical innovation, market development, channels and retail management to comprehensively improve the access of innovative drugs for chronic hepatitis B in Chinese patients. Luo Yongqing, global vice president of Gilead Sciences and general manager of China, and Liu Yong, president of China Pharmaceutical Holdings, signed the contract on behalf of the two sides.Currently, there are about 86 million HBV carriers in China. Chronic hepatitis B is a potentially life-threatening liver infection caused by the hepatitis B virus, and people with hepatitis B are at high risk of dying from cirrhosis and liver cancer. Although it is not yet possible to completely eliminate chronic hepatitis B virus, but with the upgrading of antiviral drugs in China, patients with slow hepatitis B have low resistance and better safety protection drug options, through long-term standardized treatment, reduce the risk of liver cancer.In 2018, Gilead Sciences' new slow hepatitis B drug, Viride (TAF/Fumarate propofol tablets), a new oral antiviral drug for chronic hepatitis B, was officially launched in China. At the end of 2019, Werriday will be included in the new version of the National Health Insurance Directory through the National Health Insurance Negotiations to benefit more Chinese hepatitis B patients at affordable prices. According to the agreement, China Pharmaceutical Holdings will rely on its perfect network layout, strong channel management capabilities, as well as professional marketing team and services, to further improve the access of We lied in the broad area of the grass-roots market, to help more patients with slow hepatitis B improve the quality of life, return to normal life."'May there be no more hepatitis in the world' is Gilead's vision for science, " says Mr Luo. Since our commercial operations in China began in 2017, we have rapidly introduced eight innovative global drugs and continue to drive drug access through health insurance access and multi-party collaboration. With the advantages of China National Pharmaceutical Holdings' grass-roots team and network coverage, I believe this collaboration can help more patients in need to improve treatment. Liu Yong,, said: "Since Gilead Science entered China, the two sides have carried out a series of cooperation around antiviral-related products, and today's signing opens a new chapter in strategic cooperation." We will give full play to the brand, channels, network and many other advantages, and constantly improve We lied's terminal medical coverage, so that more patients with hepatitis B in China benefit. In the future, we hope that the two sides will further strengthen cooperation to continuously meet the growing health needs of the people and contribute to the development of China's medical and health care industry. "(Xinhua)